Hysteroscopic endometrial ablation using the rollerball electrode.
OBJECTIVE
To assess the efficacy of hysteroscopic endometrial ablation with the rollerball resectoscope.


METHODS
From April 1989 to March 1991, 64 women underwent hysteroscopic endometrial ablation using electrosurgery. Telephone follow-up was obtained for 61 patients at least 6 months after the procedure. The majority of patients requested endometrial ablation because of irregular heavy menses, and two patients presented with postmenopausal bleeding. All patients had preoperative endometrial sampling that demonstrated benign endometrial histology. Five women had previous endometrial ablation with the Nd:YAG laser, with persistent bleeding. Eight patients had endometrial polyps and six had submucous fibroids that were resected at the time of hysteroscopic ablation.


RESULTS
The average operative time was 31.6 minutes, and an average of 304 mL of distending medium was absorbed during the procedure. Complications included one uterine perforation in a patient who had a previous Nd:YAG ablation, and one epidural anesthetic complication. At follow-up, 18 women (29.5%) reported amenorrhea, 16 (26.2%) reported spotting, 21 (34.4%) reported decreased menstrual flow, four (6.6%) had no change, and two (3.3%) noted increased flow. Subjectively, 49 patients (80.3%) reported a satisfactory outcome. Of the 12 who were not satisfied, seven underwent a repeat ablation with satisfactory results, four chose hysterectomy, and one elected not to have further therapy.


CONCLUSIONS
Endometrial ablation with the rollerball electrode is a safe, excellent method of management in women with excessive menstrual flow and provides a cost-effective, minimally invasive alternative to hysterectomy.
Daniell
J F
JF
Department of Obstetrics and Gynecology, Centennial Medical Center, Nashville, Tennessee.
Kurtz
B R
BR
Ke
R W
RW
D000328:Adult; D003613:Danazol / Q000627:therapeutic use; D004598:Electrosurgery / Q000379:methods*; D004717:Endometrium / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D015907:Hysteroscopy; D008875:Middle Aged; D017060:Patient Satisfaction; D011300:Preoperative Care; D014592:Uterine Hemorrhage / Q000453:epidemiology / Q000601:surgery*
D007987:Gonadotropin-Releasing Hormone; D003613:Danazol